Fremanezumab in real-life clinical practice: specialized headache center experience

Fremanezumab in real-life clinical practice: specialized headache center experience

Anti-CGRP monoclonal antibodies (mAb) have been approved and successfully used in Russia since 2020.Objective: to investigate the efficacy and safety of fremanezumab (FRE) therapy (225 mg monthly or 675 mg quarterly) in real-life clinical practice in patients with migraine who referred to a speciali...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. E. Azimova, K. V. Skorobogatikh, V. V. Osipova, D. Z. Korobkova, N. V. Vashchenko, E. Z. Mamkhegov, A. S. Galanina, E. A. Guziy
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2024-06-01
Series:Неврология, нейропсихиатрия, психосоматика
Subjects:
migraine
monoclonal antibodies
fremanezumab
ajovi
Online Access:https://nnp.ima-press.net/nnp/article/view/2288
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://nnp.ima-press.net/nnp/article/view/2288

Similar Items